Solvonis Therapeutics plc (SLVNF)

OTCMKTS · Delayed Price · Currency is USD

0.0020

-0.0005 (-20.00%)

At close: Jun 5, 2026

Market Cap	16.19M -3.1%
Revenue (ttm)	n/a
Net Income	-7.73M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,010
Open	0.0020
Previous Close	0.0025
Day's Range	0.0020 - 0.0020
52-Week Range	0.0001 - 0.0070
Beta	1.19
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorde... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2017

Employees 6

Stock Exchange OTCMKTS

Ticker Symbol SLVNF

Financial Performance

Financial numbers in GBP Financial Statements